Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Lens Clear all
Terminated Not applicable Interventional

Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria

NCT00785135
View directory record Official record
Conditions
Binocular Dysfunction, Vertical Heterophoria, Vision, Binocular, Vision Disparity
Interventions
Lenses containing prismatic correction, Lenses not containing prismatic correction
Device
Lead sponsor
Vision Specialists of Birmingham
Other
Eligibility
14 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Birmingham, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 13, 2026, 7:35 AM EDT
Completed No phase listed Observational

LENS - Long-term Eltrombopag Observational Study

NCT00643929
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure

NCT00804999
View directory record Official record
Conditions
Normal Contact Lens Wear
Interventions
Clear Care, ReNu, OPTI-FREE
Drug
Lead sponsor
Christine Sindt
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

NCT00703781
View directory record Official record
Conditions
Cataract
Interventions
bromfenac ophthalmic solution, placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 13, 2026, 7:35 AM EDT
Terminated Not applicable Interventional Results available

The Effect of Low-Level Laser Stimulation on Hearing Thresholds

NCT01820416
View directory record Official record
Conditions
Hearing Loss
Interventions
Low-level Laser Therapy, Placebo Comparator: Disabled Laser
Radiation · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurolens Headache Study

NCT05070767
View directory record Official record
Conditions
Binocular Vision Disorder, Convergence Insufficiency, Headache, Computer Vision Syndrome
Interventions
Neurolens spectacle lens, Placebo spectacle lens
Device
Lead sponsor
Neurolens Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Conyers, Georgia • Perry, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 13, 2026, 7:35 AM EDT
Not yet recruiting Not applicable Interventional

Circadian Light Exposure Adjustment for Restfulness

NCT07391852
View directory record Official record
Conditions
Sleep Onset Latency
Interventions
Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
Device
Lead sponsor
University of Arizona
Other
Eligibility
60 Months to 83 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 13, 2026, 7:35 AM EDT
Terminated Phase 1 Interventional

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

NCT04500574
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost eluting contact lens, Topical Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.

NCT06780306
View directory record Official record
Conditions
Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
Interventions
TTAX03, Saline (NaCl 0,9 %) (placebo)
Biological
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Berkeley, California • Deerfield Beach, Florida • Chaska, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 13, 2026, 7:35 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Ocular Hygiene on Scleral Lens Wear

NCT03544385
View directory record Official record
Conditions
Scleral Contact Lenses
Interventions
Ringers Solution, Placebo - Concentrate
Drug
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

NCT00889252
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
contact lens with ketotifen, contact lens
Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

NCT00445874
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen with a Contact Lens (no generic name)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Irvine, California • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis

NCT00432757
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen with a Contact Lens (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Los Angeles, California • Charlotte, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Sep 13, 2026, 7:35 AM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 13, 2026, 7:35 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

NCT04806503
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Seeing the World Through Assorted Glasses

NCT02483559
View directory record Official record
Conditions
Sleep
Interventions
Amber Lenses, Placebo Lenses
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3

NCT02950545
View directory record Official record
Conditions
Astigmatism
Interventions
Placebo Lenses, Spherical Lenses, Toric Lenses
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 39 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 13, 2026, 7:35 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Neurolens Convergence Insufficiency Study

NCT05087563
View directory record Official record
Conditions
Binocular Vision Disorder, Convergence Insufficiency, Computer Vision Syndrome
Interventions
Neurolens spectacle lens, Placebo spectacle lens
Device
Lead sponsor
Neurolens Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Brea, California • Fort Collins, Colorado • Manchester, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 13, 2026, 7:35 AM EDT
Withdrawn Not applicable Interventional

Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC)

NCT04240587
View directory record Official record
Conditions
Contact Allergy, Neuropathic Pain
Interventions
TrueTear™ intranasal neurostimulator (ITN)
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT05133518
View directory record Official record
Conditions
Cataract
Interventions
MELT-300, Midazolam alone, Ketamine alone, Placebo
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Etafilcon A With Ketotifen

NCT03388138
View directory record Official record
Conditions
Visual Acuity
Interventions
etafilcon A with ketotifen, 1-Day ACUVUE
Combination Product · Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
6
States / cities
Jacksonville, Florida • Maitland, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 13, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

NCT02163824
View directory record Official record
Conditions
Ocular Infections, Irritations and Inflammations
Interventions
KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
23
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 13, 2026, 7:35 AM EDT